Table 11 Liquid biopsy in endocrine system cancers
From: Liquid biopsy in cancer: current status, challenges and future prospects
Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
TC | CTCs | Peripheral blood | up | Â | Early diagnostic biomarker | |
CTCs | Peripheral blood | up | Â | Efficacy monitoring biomarker | ||
ctDNA mutation | Plasma | up | Â | Efficacy monitoring biomarker | ||
ctDNA | Plasma | up | Â | Disease progression biomarker | ||
BRAFV600E mutation | Plasma | up | Â | Efficacy monitoring biomarker | ||
RET M918T mutation | Plasma | up | Â | Prognostic biomarker | ||
BRAF(T1799A) mutation | Plasma | up | Â | Disease progression biomarker | ||
PIK3CA mutation | Peripheral blood | up | Â | Prognostic biomarker | ||
SLC5A8, SLC26A4 methylation | Plasma | up | BRAF | Early diagnostic biomarker | ||
ctDNA methylation | Serum | up | Â | Early diagnostic biomarker, Tumor recurrence biomarker | ||
miR-146b-5p, miR-21a-5p | Plasma exosome | up | Â | Early diagnostic biomarker | ||
miR-29a | Serum exosome | down | Â | Early diagnostic biomarker, Prognostic biomarker | ||
BRCA | CTCs | Peripheral blood | up | Â | Prognostic biomarker, Efficacy monitoring biomarker | |
TP53, PIK3CA, ESR1 mutation | Plasma | up | Â | Efficacy monitoring biomarker | ||
ctDNA mutation | Plasma | up | Â | Efficacy monitoring biomarker, Tumor recurrence biomarker | ||
PIK3CA mutation | Plasma | up | Â | Early diagnostic biomarker, Efficacy monitoring biomarker, Tumor recurrence biomarker | ||
miR-1246, miR-21 | Plasma exosome | up | Â | Early diagnostic biomarker | ||
miR-101, miR-372 | Serum exosome | up | Â | Early diagnostic biomarker | ||
miR-106a-3p, miR-106a-5p, miR-20b-5p, miR-92a-2-5p | Serum exosome, Plasma exosome | up | Â | Early diagnostic biomarker |
